News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to ...

Although medications with glucagon-like peptide-1 (GLP-1) receptor agonist activity have transformed the management of obesity and shown substantial cardiometabolic benefits, unmet needs remain.

Boehringer Ingelheim’s survodutide phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing ...

New data highlight the potential benefits of survodutide, a once-weekly injectable therapy targeting both the glucagon and glucagon-like peptide-1 (GLP-1) receptors in individuals with obesity and ...

Until now, research into type 2 diabetes has focused primarily on insulin: if the body's cells become less responsive to the hormone produced in the pancreas, blood glucose levels rise over the long ...

The GLP-1 agonists weight loss drugs market offers growth potential through rising obesity rates, innovative drug approvals, and increased insurance coverage. Opportunities include expanding obesity ...

Fresenius Kabi announced the launch of Glucagon Emergency Kit for the treatment of severe hypoglycemic episodes in adult and pediatric patients with diabetes. Fresenius Kabi announced the launch of ...

Glucagon increases the production of glucose by increasing glycogenolysis and gluconeogenesis in the liver, and by reducing glycogenesis and glycolysis. The release of glucagon in response to food ...